↓ Skip to main content

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

Overview of attention for article published in Frontiers in oncology, January 2022
Altmetric Badge

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells
Published in
Frontiers in oncology, January 2022
DOI 10.3389/fonc.2022.794216
Pubmed ID
Authors

Hongxia Li, Yaping Wang, Rina Su, Yuchen Jia, Xiong Lai, Huimin Su, Yaochun Fan, Yuewu Wang, Wanjin Xing, Jianzhong Qin

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 17%
Researcher 2 17%
Student > Ph. D. Student 2 17%
Student > Bachelor 1 8%
Professor > Associate Professor 1 8%
Other 1 8%
Unknown 3 25%
Readers by discipline Count As %
Unspecified 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 17%
Biochemistry, Genetics and Molecular Biology 2 17%
Neuroscience 1 8%
Medicine and Dentistry 1 8%
Other 0 0%
Unknown 4 33%